Drug interactions
Larotrectinib + Rolapitant
Severity: Minor
Larotrectinib and Rolapitant: minor interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Larotrectinib is a CYP3A4 substrate and weak inhibitor, so effects on rolapitant exposure are expected to be small. The direction and significance are not well established.
What this interaction means in plain words
Larotrectinib and Rolapitant have a small, usually unimportant interaction. Most people can take both; the pharmacist may still mention it so that any unexpected effect is recognised.
Larotrectinib belongs to Oncology; Rolapitant belongs to Gastrointestinal Tract.
Why it happens
Possible weak CYP3A4 inhibition by larotrectinib; the mechanism is not firmly established.
What to do
No dose adjustment is required. Monitor for rolapitant adverse effects.
What to ask your pharmacist
- Is there anything I should notice while taking both?
- Do I need to tell my doctor at the next visit?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Larotrectinib and Rolapitant, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 14 days on the web. No card needed.
Other interactions of Rolapitant
- Pimozide + Rolapitant Contraindicated
- Rolapitant + Thioridazine Contraindicated
- Atomoxetine + Rolapitant Major
- Deutetrabenazine + Rolapitant Major
- Eliglustat + Rolapitant Major
- Flecainide + Rolapitant Major
Other interactions of Larotrectinib
Frequently asked questions
Can I take Larotrectinib with Rolapitant?
MediHelp rates the interaction as minor. Larotrectinib and Rolapitant have a small, usually unimportant interaction. Most people can take both; the pharmacist may still mention it so that any unexpected effect is recognised. Larotrectinib is a CYP3A4 substrate and weak inhibitor, so effects on rolapitant exposure are expected to be small. The direction and significance are not well established.
How serious is the interaction between Larotrectinib and Rolapitant?
MediHelp rates it minor, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: No dose adjustment is required. Monitor for rolapitant adverse effects.
What other medicines interact with Rolapitant?
MediHelp also lists interactions of Rolapitant with, for example, Pimozide, Thioridazine, Atomoxetine. The full list is on the Rolapitant page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
